10-K: Biotricity Inc. Reports Fiscal Year 2026 Results

Biotricity Inc. announced its fiscal year 2026 results, showing revenue growth and a reduced net loss, while highlighting ongoing product development and market expansion.

Summary

• Biotricity Inc. reported revenue of $16.0 million for the fiscal year ended March 31, 2026, a 16.0% increase from the previous year.
• The company reduced its net loss attributable to common stockholders to $3.13 million from $11.9 million in the prior fiscal year.
• Total operating expenses decreased to $11.25 million from $13.0 million, primarily due to a reduction in selling, general, and administrative expenses.
• Research and development expenses increased to $2.8 million, reflecting continued investment in new technologies and product enhancements.
• The company's gross profit margin improved to 81% from 76.6%, driven by an increase in higher-margin technology sales.
• Biotricity continues to expand its sales efforts, now covering 35 U.S. states, with plans for further market penetration.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the company's continued net losses, significant accumulated deficit, low liquidity, and the auditor's going concern opinion, despite some revenue growth and improved gross margins.

Positives

• Revenue increased by 16.0% to $16.0 million for the fiscal year ended March 31, 2026.
• Net loss attributable to common stockholders decreased significantly to $3.13 million from $11.9 million in the prior year.
• Gross profit margin improved to 81% due to a favorable shift in revenue mix towards higher-margin technology sales.
• Total operating expenses decreased by $1.75 million, primarily due to cost efficiencies in selling, general, and administrative expenses.
• Adjusted EBITDA showed a positive trend, improving to $702 thousand for the quarter ended March 31, 2026, from $435 thousand in the prior year's comparable period.
• The company has expanded its sales presence to 35 U.S. states, indicating market growth and adoption.

Negatives

• The company reported an accumulated deficit of $142.57 million as of March 31, 2026.
• Biotricity has a working capital deficit of $31.3 million as of March 31, 2026.
• The company's auditors have included a going concern opinion due to recurring losses and negative cash flows from operations.
• Cash and cash equivalents were $149,789 as of March 31, 2026, indicating limited liquidity.
• The company's common stock is traded on the OTCQB, and its market price was $0.236 as of March 31, 2026.

Risks

• The company's limited operating history and history of net losses raise substantial doubt about its ability to continue as a going concern.
• Failure to secure additional funding could compromise the company's ability to execute its business plan and may require curtailment of operations.
• The company is subject to extensive governmental regulations for medical devices, and failure to comply could result in enforcement actions.
• Product defects or manufacturing issues could lead to recalls, safety alerts, and product liability claims.
• Dependence on third-party wireless carriers for data transmission poses a risk of service interruption.
• The company faces intense competition from larger, well-resourced medical device companies.
• Intellectual property litigation and infringement claims could result in significant expenses and hinder product sales.
• Changes in healthcare reimbursement policies or a decline in physician utilization of arrhythmia monitoring solutions could negatively impact revenue.

Future Outlook

The company anticipates continued improvement in overall blended gross margin over time due to the evolving revenue mix and economies of scale. Management believes existing cash, along with anticipated near-term financings, will be sufficient to meet needs for the next twelve months, but additional debt or equity capital will be required for future growth and to respond to business opportunities and challenges.

Management Comments

• We believe our solutions insourcing model, which empowers physicians with state-of-the-art technology and charges technology service fees for its use, has the benefit of a reduced operating overhead for the Company, and enables a more efficient market penetration and distribution strategy.
• The Company identified the importance of recent developments in accelerating its path to profitability, including the launch of important new products identified, which have a ready market through cross-selling to existing large customer clinics, and large new distribution partnerships that allow the Company to sell into large hospital networks.
• Management has taken certain action and continues to implement changes designed to improve the Companys financial results and operating cash flows. The actions involve certain cost-saving initiatives and growing strategies.

Industry Context

StockSavvy.ai notes that Biotricity operates in the growing remote patient monitoring and cardiac diagnostics market, which is driven by an aging population and increasing prevalence of chronic diseases. The company's focus on an insourcing model and integrated technology platform differentiates it from competitors who often rely on outsourced services.

Comparison to Industry Standards

• Biotricity's gross profit margin of 81% for FY2026 is strong, particularly compared to the broader medical device industry average, which can vary significantly but often falls in the 50-60% range.
• The company's revenue growth of 16.0% is solid, aligning with or exceeding growth rates seen in segments of the connected health market, which is projected to grow at a CAGR of 25% according to MarketUs.
• Biotricity's R&D investment of $2.8 million represents approximately 17.5% of its revenue, which is a significant commitment to innovation, comparable to or higher than many early-stage medical technology companies investing in new product development.

Corporate Governance

Legal Proceedings

• The company is not currently a party in any material legal proceeding where it is a defendant, or governmental regulatory proceeding.

Related Party Transactions

• Trade and other payables and accrued liabilities as at March 31, 2026 and 2025 included $1,053,228 and $373,744, respectively, due to a shareholder, who is a director and executive of the Company.

Stakeholder Impact

• Shareholders: Continued losses and low liquidity may impact stock value and future returns. Potential dilution from future capital raises is a concern.
• Creditors: The company's substantial indebtedness and going concern issues could impact its ability to meet debt obligations.
• Employees: The company plans to hire additional employees to support growth, but financial instability could pose employment risks.
• Suppliers: The company relies on a limited number of suppliers, and any disruption could impact operations.

Next Steps

• Continue to expand sales force and geographic footprint.
• Pursue further FDA clearances for ancillary technologies.
• Seek additional debt or equity capital to fund operations and growth.
• Continue to develop and enhance the Bioflux and Biocore platforms.
• Expand into future markets such as implantable cardiac device monitoring and chronic care management for diabetes and sleep apnea.

Key Dates

Recommendation

Despite some positive operational improvements like revenue growth and margin expansion, the company's severe liquidity constraints, substantial accumulated deficit, and the auditor's going concern opinion present significant risks. The need for substantial future financing, which may be dilutive, further increases the risk profile. Investors should consider the high probability of continued unprofitability and the potential for further share price depreciation.

Keywords

Biotricity Inc., Form 10-K, Annual Report, Medical Technology, Remote Patient Monitoring, Cardiac Monitoring, Biocore, Bioflux